Soleno therapeutics inc
SLNO 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分中等，已經有部位可以持續持有，若想建立新部位可以等待價值評分轉變為4分以上、股利提升為2分以上
SLNO 近期報酬表現
6.45%
Soleno therapeutics inc
2.06%
同產業平均
-0.34%
S&P500
與 SLNO 同產業的標的表現
| 股票代碼 | 公司名稱 | 價值 | 趨勢 | 波段 | 籌碼 | 股利 | 加入追蹤 |
|---|---|---|---|---|---|---|---|
SPRC | Scisparc ltd | - | 2 分 | 2 分 | - | 1 分 | |
FEMY | Femasys inc | - | 5 分 | 2 分 | 1 分 | 1 分 | |
AYTU | Aytu biopharma inc | 2 分 | 3 分 | 2 分 | 1 分 | 1 分 | |
BRNS | Barinthus biotherapeutics plc - adr | - | 2 分 | 2 分 | 1 分 | 1 分 | |
BHVN | Biohaven ltd | - | 2 分 | 1 分 | 3 分 | 1 分 |
- SPRC Scisparc ltd價值 -趨勢 2 分波段 2 分籌碼 -股利 1 分查看更多
SLNO 公司資訊
Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), recently completed its Phase 3 development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR's mode of action with targets in the brain, pancreas and fat tissue has the potential to impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and an orphan designation for the drug in the United States and the European Union.